Clinical trials: Refractory Shock
Refractory Angina Pectoris
Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with…
- Trial name
- NCT01241968
- Testing
- Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Medispec
Septic Shock, Extracorporeal Membrane Oxygenation Complication
Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock
Severe sepsis and septic shock remain the leading causes of child mortality worldwide. Sepsis is a complex process that ultimately leads to circulation disorders, organ perfusion abnormalities, capillary leakage, tissue hypoxia…
- Trial name
- NCT03948048
- Testing
- ECMO
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Multiple Myeloma, Cytokine Release Syndrome
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
The purpose of this study is to examine the safety, efficacy and feasibility of the use of one standard dose of siltuximab prior to teclistamab infusion.
- Conditions
- Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- NCT06352866
- Testing
- Siltuximab, Teclistamab(FDA-approved)
- Where
- United States
- Sponsor
- Jack Khouri, MD
Septic Shock, Vasopressor Resistance
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock
Septic shock is one of the most frequent reasons for admission to intensive care units and remains associated with a high mortality rate of approximatively 40% at 28 days.
- Trial name
- ADRESS (NCT07569536)
- Testing
- Dexmedetomidine 100 µg/mL, intravenous solution, Stardard care
- Where
- 18 sites in France
- Volunteers
- 360 people
- Sponsor
- Hospices Civils de Lyon
Interstitial Cystitis
Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis
Low energy shock wave (LESW) is known to facilitate tissue regeneration with analgesic and anti-inflammatory effects. LESW treatment has been demonstrated effective in treatment of nonbacterial prostatitis and chronic pelvic pain…
- Trial name
- NCT05275647
- Testing
- BOTOX 100U in normal saline, Normal saline
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Refractory Angina Pectoris, Ischemic Heart Disease
Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the…
- Conditions
- Refractory Angina Pectoris, Ischemic Heart Disease, Coronary Artery Disease
- Trial name
- NCT03438500
- Testing
- Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)
- Where
- Germany
- Sponsor
- Storz Medical AG
Cardiogenic Shock, Refractory Shock
Levosimendan for Veno-arterial ECMO Weaning
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support that has been increasingly used over the last decade to restore and maintain adequate end-organ perfusion, with data…
- Trial name
- WEANECMO (NCT04323709)
- Testing
- Data collection, Data analysis
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Fluid Refractory Septic Shock, Septic Shock
Adrenaline V/s Dopamine in Fuid Refractory Septic Shock
This study compares the efficacy of two drugs i.e Adrenaline and dopamine in fluid refractory type of septic shock which is a dreadful medical condition especially in children.
- Trial name
- NCT07273526
- Testing
- Adrenaline, Dopamine
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Laiba Qamar
Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- Trial name
- NCT05972135
- Testing
- Teclistamab, Talquetamab, Tocilizumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Septic Shock
Dopamine Versus Epinephrine for Pediatric Fluid-Refractory Hypotensive Septic Shock
This randomized clinical trial was conducted to compare dopamine with epinephrine as the first vasoactive treatment in children aged 2 to 12 years with fluid-refractory hypotensive septic shock.
- Trial name
- NCT07775001
- Testing
- Epinephrine, dopamine
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Nishtar Medical University
Cytokine Release Syndrome, Recurrent Multiple Myeloma
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period…
- Conditions
- Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07657312
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Naresh Bumma
Shock, Hypovolemia
Vasopressin in Traumatic Hemorrhagic Shock Study
The purpose of the present trial is therefore to assess effects of arginine vasopressin vs. saline placebo on hospital admission rate (primary end point), as well as hemodynamic variables, fluid resuscitation requirements and…
- Conditions
- Shock, Hypovolemia, Hemorrhagic Shock
- Trial name
- NCT00379522
- Testing
- Vasopressin
- Where
- 14 sites in Austria, Germany
- Volunteers
- 64 people
- Sponsor
- Volker Wenzel
Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell…
- Trial name
- NCT07897136
- Testing
- CLL-1-CD70 CAR-T Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
B Cell Malignancies, B-cell Leukemia
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter.
- Conditions
- B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells
- Trial name
- BaseCAR-01 (NCT07166549)
- Testing
- Experimental Intervention
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Basel, Switzerland
Urinary Bladder, Overactive
Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women
Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage.
- Trial name
- NCT07739550
- Testing
- Low-Intensity Extracorporeal Shock Wave Therapy
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Al-Azhar University
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in…
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NexCAR19 (NCT07502118)
- Testing
- Talikabtagene Autoleucel
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Health Institutes of Turkey
Acute Respiratory Distress Syndrome, Cardiogenic Shock
Closed Loop Mechanical Ventilation and ECMO
Mechanical ventilation and ECMO are both technologies interacting on gas exchange. Nevertheless, besides a consensus paper, no evidence-based guidelines regarding protective lung ventilation on ECMO exist to date.
- Trial name
- NCT04925518
- Testing
- Closed Loop Mechanical Ventilation, Conventional Mechanical Ventilation
- Volunteers
- 62 people
- Sponsor
- University of Zurich
Cardiogenic Shock Acute
Early Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used worldwide to treat severe cardiogenic shock.
- Trial name
- EULODIA (NCT07027202)
- Testing
- Early Left Ventricle unloading
- Where
- 12 sites in France
- Volunteers
- 298 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Septic Shock, Refractory Shock
Terlipressin for Refractory Septic Shock
Norepinephrine was recommended as the first vasopressor for septic shock resuscitation. For the patient who did not response to high dose norepinephrine, epinephrine was recommended.
- Conditions
- Septic Shock, Refractory Shock, Norepinephrine Adverse Reaction
- Trial name
- TERESEP (NCT04339868)
- Testing
- Terlipressin
- Where
- Thailand
- Volunteers
- 130 people
- Sponsor
- Mahidol University